目的 建立考察苯丙氨酯片溶出过程的方法，比较不同厂家的生产工艺及质量。方法 以对照品法，利用FODT-601FX光纤药物溶出度实时测定仪实时监测苯丙氨酯片的溶出过程，并采用相似因子（f₂）对溶出曲线进行一致性评价。结果 选择0.5 mm探头，260 nm为测定波长，苯丙氨酯浓度在20～130 μg/mL与吸光度具有良好的线性关系，r=0.999 9。考察了市售的5个厂家（A～E厂）11个批次的苯丙氨酯产品在水中的溶出曲线，除D厂外各批次苯丙氨酯片的溶出度检查结果均符合日本橙皮书的规定，但各厂家苯丙氨酯片的溶出曲线存在一定差异，选取样品C1作为参比制剂，有A、C2、C3、E样品的溶出曲线与C1相似（50≤f₂≤100），而B、D厂样品的溶出曲线与C1明显不同（f₂<50）。结论 光纤法溶出度能客观反映苯丙氨酯片溶出全过程，监测的5个厂家生产的苯丙氨酯片存在药品溶出过程不相似以及部分厂家内在质量差异较大的问题。

Objective To compare the differences in intrinsic qualities of products by observing dissolving-out process of phenporbamate tablets from different manufacturers. Methods The fiber-optic real-time dissolution detector was used and conditions adopted for dissolution were in accordance with detecting conditions of phenporbamate tablets dissolution, and similar factor method (f₂) was also used to evaluate differences of dissolution values of different manufacturer's phenporbamate tablets. Results Phenporbamate tablets was monitored at light path 0.5 mm and wave length 260 nm, and its absorbability was better with concentration at range of 20-130 μg/mL, r=0.999 9. Phenporbamate tablets from 11 different batches and 5 different manufacturers (A-E) conformed to the national drug standards (except D), but differences were found in the dissolution curves of those drugs. C1 was used as the reference preparation, only samples A, C2, C3 and E had similar dissolution process with C1's dissolution process (50 ≤ f₂ ≤ 100). However, both samples B and D had clear differences in their dissolution when compared to the dissolution process of C1 (f₂ < 50). Conclusion Fiber optic dissolution test system can objectively reflect the whole dissolving process of phenporbamate tablets.

广西食品药品安全科研项目（KY2017-03）